Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Oct 16, 2024 5:02pm
103 Views
Post# 36268905

RE:RE:Updated Presentation

RE:RE:Updated Presentation These are ONCY's own slides... their timelines... and you can bet they're presenting a best possible case...

If I were to put a real dampener on things, I'd suggest looking at previous trial timelines.

2) Matt is on record stating that Aware-1 would take a few months (Apr 2019) - it took 3+ years
3) Their only partner no longer mentions Pela., and yet they have a green light from CFDA to run a Phase III for Pela + Pax vs Pax.
4) IND-213 that they still refer to in their slidedeck, and which will be half the randomised data for an accelerated approval submission, started in 2012...!! Almost 13 years ago... 

The recent share price explosion only gets the PPS back to where it was in early summer. These crazy dips are worth exploiting, but buy and hold in this company is an exercise in futility. 

glta
<< Previous
Bullboard Posts
Next >>